Lexicon Pharmaceuticals Enters License Agreement With Novo Nordisk for Obesity Drug; Shares Jump

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Lexicon Pharmaceuticals Enters License Agreement With Novo Nordisk for Obesity Drug; Shares Jump

, MT Newswires - 8:11 AM ET 3/28/2025 default

08:11 AM EDT, 03/28/2025 (MT Newswires) -- Lexicon Pharmaceuticals ( LXRX ) said Friday that it signed an exclusive license agreement with Novo Nordisk ( NVO ) for LX9851, a drug targeting obesity and associated metabolic disorders, sending shares up more than 94% in premarket activity.

Under the agreement, Novo Nordisk ( NVO ) gains the exclusive worldwide rights to develop, manufacture, and commercialize LX9851 across all indications.

Lexicon said it will be responsible for the completion of investigational new drug application-enabling activities for LX9851, while Novo Nordisk ( NVO ) will take over responsibility for filing the application and all subsequent development, manufacturing, and commercialization efforts.

Under the deal, Lexicon is eligible to receive up to $75 million in upfront and near-term milestone payments, a potential for $1 billion in development, regulatory, and sales milestones and tiered royalties on net sales.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.